BURDEN OF BRAIN METASTASES (BM) IN ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Pan, X. [1 ]
Kwon, C. S. [2 ]
Garib, S. A. [2 ]
Forsythe, A. [2 ]
Lin, H. M. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Purple Squirrel Econ, New York, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN22
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [21] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [22] Economic burden of brain metastases in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung
    Lin, Huamao Mark
    Pan, Lucy
    Hou, Peijie
    Huang, Hui
    Desai, Avinash
    Jahanzeb, Mohammad
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [23] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [24] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK plus non-small cell lung cancer (NSCLC) treated with ALK inhibitors
    Biber, Josh
    Wan, Yin
    Churchill, Eric N.
    Danes, Christopher G.
    Socinski, Mark A.
    Spira, Alexander I.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E36 - E36
  • [26] Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3
    Park, K.
    Tan, D.
    Ahn, M. -J.
    Yu, C. -J.
    Tsai, C. -M.
    Hida, T.
    Nishio, M.
    Branle, F.
    Emeremni, C.
    Mok, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 126 - 127
  • [27] Non-small Cell Lung Cancer (NSCLC) ALK plus NSCLC: Lorlatinib enables sustained high systemic and intracranial Efficacy in the First Line
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [28] ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences
    Cicin, Irfan
    Martin, Claudio
    Haddad, Carolina Kawamura
    Kim, Sang -We
    Smolin, Alexey
    Abdillah, Arif
    Yang, Xue
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [29] A Patient-Centric, Phase II Trial of First-Line Lorlatinib&alk TKIs in China Advanced ALK plus Non-Small Cell Lung Cancer
    Lin, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S659 - S659
  • [30] ALK plus Non-Small Cell Lung Cancer Treated with First Line Crizotinib: Patient Characteristics, Treatment Patterns, and Survival
    Martin, C.
    Cardona, A.
    Arrieta, O.
    Castillo-Fernandez, O.
    Oblitas, G.
    Corrales, L.
    Lupinacci, L.
    Perez, M. A.
    Rojas, L.
    Gonzalez, L.
    Chirinos, L.
    Ortiz, C.
    Lema, M.
    Vargas, C.
    Puparelli, C.
    Carranza, H.
    Otero, J.
    Ramirez-Tirado, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1899 - S1900
12345